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Due to the improvement of therapy in cystic ﬁbrosis (CF) life expectations and
quality of life improved signiﬁcantly but patients’ huge effort was required as well.
‘Saturday’s child works hard for a living” from the old poem could be dated back
to this era. The main part of patients’ hard work is the two hour long physiotherapy
on a daily basis. High frequency chest wall oscillation (HFCWO) makes it simpler
and faster.
Therapy was carried out by HRVS 104 equipment for 10 minutes twice a day.
Frequency and intensity were adjusted to the patients. Spirometric parameters,
diffusing capacity and the change in alveolar space/alveolar dead space ratio were
studied in 23 CF patients before and after the treatment. Besides these examinations
we asked for the patients’ and the operators’ opinion.
Treatment with HFCWO lasted for two weeks on average. When compared to
the values before therapy the following factors improved signiﬁcantly after treat-
ment: DFVC = 17.6±17.3%, DFEV1 = 22.2±22.4%, DRV/TLC% = −34±22%,
DDLCO% = 12.4±14.7%, DVt/Vd = 43±17%. Besides the mechanic clearance
of discharge HFCWO reduced atelectasis, ventillation-perfusion inequalities and
improved alveolar ventilation. Patients found this method an effective way of
physiotherapy. Physiotherapists appreciated the simplicity of this method in the
case of patients at a younger age when other methods are hard to use.
HFCWO is the most physiological way to mobilize and remove bronchial discharge
and to improve gas exchange. It is very simple to use even at a younger age, easy to
learn to use for anyone anywhere, and makes daily bronchial hygiene signiﬁcantly
shorter.
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Single-session cross-over trials suggest that NIV assists CPT for people with CF.
No longer-term trials have been reported. We aimed to evaluate the effect of NIV-
assisted CPT for CF adults during a hospital admission for an acute exacerbation.
Participants were included if their FEV1 was less than 60% pred on admission and
excluded if they had respiratory failure or contra-indications to NIV. The control
group received standard comprehensive inpatient care. The NIV group received the
same care plus NIV during CPT from day 2 of admission until discharge (average
IPAP 13±2cmH2O, EPAP 5±1cmH2O, daily use 65±31 mins). 40 subjects enrolled
(29±8 yr, FEV1 38±10%), 21 allocated to the control and 19 to the NIV group. The
groups were similar at admission. The NIV group had a signiﬁcantly higher FEV1
at discharge than the control group (mean difference 4.2% pred, 95% CI 0.1 to 8.3).
There was a non-signiﬁcant trend for the NIV group to have a greater daily rate of
improvement in FEV1 than the control group (mean difference 0.13% pred per day,
95%CI −0.03 to 0.28). The NIV group reported signiﬁcantly lower levels of fatigue
on the Schwartz fatigue scale at discharge than the control group (mean difference
6, 95% CI 1 to 11). The NIV group had a signiﬁcantly lower Ps aeruginosa colony
count than the control group on day 7 (mean difference 1.12 logCFU/g, 95% CI
0.04 to 2.20), but the difference was not signiﬁcant at discharge. There was no
signiﬁcant difference between the NIV and control group in the length of hospital
admission or time to next hospital admission. NIV-assisted CPT during a hospital
admission for an acute exacerbation of CF signiﬁcantly improved FEV1 and fatigue.
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It is well documented that NIV is commonly used to manage type II respiratory
failure and support airway clearance in Cystic Fibrosis (CF). There is however little
guidance on the practical application of this modality in this patient group.
This investigation surveyed clinical practice within UK adult CF centres. A
questionnaire was sent to a named physiotherapist at each UK adult centre. Response
rate was 55% (12/22).
All centres reported use of NIV for symptomatic compensated type II respiratory
failure with 50% considering use in asymptomatic type II failure. Other indications
included use during airway clearance, exercise and surgical procedures. One centre
reported use in type I respiratory failure.
Pressure support (90%) or pressure controlled (46%) ventilation were commonly
used. 18% of centres reported use of volume controlled or volume assured modes.
Choice of ventilator was dictated by Trust protocol or local experience. Mode of
ventilation was chosen according to objective response and comfort. Centres with
access to volume controlled ventilation initiated this if response to pressure con-
trolled ventilation proved to be sub-optimal. Majority of physiotherapists surveyed
stated CF patients required higher inspiratory pressures with 62% of centres using
pressures over 25 cmH2O with 39% of centres stating no maximum limit.
This investigation demonstrated a range of approaches to the indications and
prescription of NIV in adult CF patients. Areas of consensus may provide some
guidance to clinicians; although further research is needed to determine best clinical
practice by objectively demonstrating beneﬁts and efﬁcacy of different approaches
to ventilation.
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Introduction: In Cystic ﬁbrosis (CF) the respiratory affection causes 90% of
morbid-mortality due to respiratory failure. The non-invasive mechanical ventilation
(NIV) may be useful, we compare the improvement in the gaseous exchange among
FQ patients with NIV.
Methods: A retrospective study, analyzing data from patients with CF who
presented chronic respiratory failure and received NIV during the period 1997–
2009, describing the characteristics of the NIV, respiratory function tests: FEV1,
FVC, FEV1/FVC, arterial blood gases and evolution during the treatment. The
results were expressed as means and standard deviations and applied the Wilcoxon
nonparametric test for related data.
Results: We included 9 patients, 7 men with a mean age of 21±3.7, BMI: 18.5±2.4.
The initial lung function: FEV1 816.7±208.5ml; % FEV1 25.3±7.1%; FVC
1707.8±474.3ml;% FVC 44.1±11.3%; FVC, FEV1/FVC 49.4±9.95. The initial
blood gases: PaO2: 52.9±4.6mmHg, PaCO2: 47.1±13.5mmHg, pH: 7.42±0.04.
There was difference between the initial PaO2: 52.9±4.6 with the one month PaO2:
61.7±7.8 (p 0.0011), and initial PaCO2 47.1±13.5 with PaCO2 at the end 41.2±8.8
(p 0.033). No differences in pH or respiratory function tests was found. There was
no abandonment for intolerance to treatment, and only one complication was a
pneumotho´rax that resolved with chest tube. This is the ﬁrst study in Spain until
now.
Conclusion: The NIV is well tolerated and may be useful in CF patients enrolled
with chronic respiratory failure, improves hypoxemia and decreases month hyper-
capnia from the initiation of therapy. No differences were found in the evolution of
lung function.
